Insomnia drug from Merck raises FDA safety concerns
May 21, 2013 ( WASHINGTON) -- Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.
The Food and Drug Administration released its review of the company's sleep aid, suvorexant, ahead of a public meeting on Wednesday. The pill works by temporarily blocking chemical messengers that keep people awake.
The FDA said company trials show suvorexant was better than placebo at helping people fall asleep and stay asleep. Regulators said Monday the drug's effectiveness was consistent across several doses tested by Merck & Co.
But patients taking the highest dose of the drug showed an eight-fold increase in daytime drowsiness, which could interfere with driving the next morning. Suvorexant was also associated with increased risk of suicidal thinking.
- Mom allegedly kidnaps 2 sons from Beverly
- Truck driver released after boy dies in Ind. hit-and-run
- South Korea ferry sinks; 287 missing, at least 9 dead
- ABC7 First Alert Weather Forecast
- Man stabbed in back on McKinley Park street
- Blackhawks set for playoffs Thursday with STL Blues Game 1 42 min ago
- Bulls 1st round playoff schedule vs Wizards released 50 min ago
- Barrington meeting addresses consequences of 'sexting' 7 min ago
- Skill Champ app designed for children with autism
- Police: Suspicious item on LSD was sleeping bag
- Grand jury indicts Lake Station mayor, wife
- Portland shootout injures officer, kills police dog 19 min ago
- Growing Problem: Stolen Smart Phones
- abcnews: Experts: Pistorius May Have Stumbled on Stand
- 7 in :77
17 min ago
Most Viewed StoriesMost Viewed Photos